Top

Published in:

Open Access 01-12-2017 | Original Article

Development of a core set of outcome measures for OAB treatment

Authors: Caroline Foust-Wright, Stephanie Wissig, Caleb Stowell, Elizabeth Olson, Anita Anderson, Jennifer Anger, Linda Cardozo, Nikki Cotterill, Elizabeth Ann Gormley, Philip Toozs-Hobson, John Heesakkers, Peter Herbison, Kate Moore, Jessica McKinney, Abraham Morse, Samantha Pulliam, George Szonyi, Adrian Wagg, Ian Milsom

Published in: International Urogynecology Journal | Issue 12/2017

Abstract

Introduction and hypothesis

Standardized measures enable the comparison of outcomes across providers and treatments giving valuable information for improving care quality and efficacy. The aim of this project was to define a minimum standard set of outcome measures and case-mix factors for evaluating the care of patients with overactive bladder (OAB).

Methods

The International Consortium for Health Outcomes Measurement (ICHOM) convened an international working group (WG) of leading clinicians and patients to engage in a structured method for developing a core outcome set. Consensus was determined by a modified Delphi process, and discussions were supported by both literature review and patient input.

Results

The standard set measures outcomes of care for adults seeking treatment for OAB, excluding residents of long-term care facilities. The WG focused on treatment outcomes identified as most important key outcome domains to patients: symptom burden and bother, physical functioning, emotional health, impact of symptoms and treatment on quality of life, and success of treatment. Demographic information and case-mix factors that may affect these outcomes were also included.

Conclusions

The standardized outcome set for evaluating clinical care is appropriate for use by all health providers caring for patients with OAB, regardless of specialty or geographic location, and provides key data for quality improvement activities and research.

Available only for authorised users

Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: Report from the Standardisation Subcommittee of the International Continence Society. Joint publication: Neurourol Urodyn. 2002;21(2):167–178, Urology. 2003;61:37–49.

Haylen BT, de Ridder D, Freeman RM, et al. An international Urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20. https://doi.org/10.1002/nau.20798.PubMed

Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–14.CrossRefPubMed

Milsom I, Coyne KS, Nicholson S, et al. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014;65(1):79–95. https://doi.org/10.1016/j.eururo.2013.08.031.CrossRefPubMed

Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–36.PubMed

Irwin DE, Mungapen L, Milsom I, et al. The economic impact of overactive bladder syndrome in six western countries. BJU Int. 2009;103:202–9.CrossRefPubMed

Porter ME, Lee TH. The strategy that will fix health care. Harvard Bus Rev. 2013;91:50–70.

Porter ME. What is value in health care? N Engl J Med. 2010;363:2477–81. https://doi.org/10.1056/NEJMp1011024.CrossRefPubMed

Pill J. The Delphi method: substance, context, a critique and an annotated bibliography. Socio Econ Plan Sci. 1971;5(1):57–71. https://doi.org/10.1016/0038-0121(71)90041-3.CrossRef

10.

Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 2011;64(4):395–400. https://doi.org/10.1016/j.jclinepi.2010.09.012.CrossRefPubMed

11.

Cleary PD, Meterko M, Wright SM, Zaslavsky AM. Are comparisons of patient experience across hospitals fair? A study in veterans health administration hospitals. Med Care. 2014;52(7):619–25. https://doi.org/10.1161/HYPERTENSIONAHA.113.02854.Impact.CrossRefPubMedPubMedCentral

12.

5^th International Consultation on Incontinence. Editors Abrams, Cardozo, Kouhry and Wein. Health Publications Ltd, Paris 2013.

13.

Donovan J, Abrams P, Peters T, et al. The ICS-'BPH' study: the psychometric validity and reliability of the ICSmale questionnaire. BJU. 1996;77:554–62.CrossRefPubMed

14.

Jackson S, Donovan J, Brookes S, et al. The Bristol female lower urinary tract symptoms questionnaire: development and psychometric testing. BJU. 1996;77:805–12.CrossRefPubMed

15.

Khullar V. Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure? Int Urogynecol J. 2012;23:179–92.CrossRefPubMed

16.

Coyne KS, Thompson CL, Lai JS, Sexton CC. An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF. Neurourol Urodyn. 2015;34(3):255–63.CrossRefPubMed

17.

Frankel S, Donovan J, Peters T, et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol. 1998;51(8):677–85.CrossRefPubMed

18.

Colman S, Chapple C, Nitti V, et al. Validation of treatment benefit scale for assessing subjective outcomes in treating overactive bladder. Female Urology. 2008;72(4):803–7. https://doi.org/10.1016/j.urology.2008.05.033.CrossRefPubMed

19.

Sand PK, Miklos J, Ritter H, Appell R. A comparison of extended-release oxybutynin and tolterodine for treating overactive bladder in women. Int Urogynecol J Pelvic Floor Dysfunct. 2004;15(4):243–8.PubMed

20.

Steers W, Corcos J, Foote J, Kralidis G. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int. 2005;95(4):580–6.CrossRefPubMed

21.

Layton D, Pearce G, Shakir S. Safety profile of tolterodine as used in general practice in England. Drug Saf. 2001;24(9):703–13.CrossRefPubMed

22.

Michel MC, Schneider T, Krege S, Goepel M. Does gender or age affect the efficacy and safety of tolterodine? J Urol. 2002;168(3):1027–31.CrossRefPubMed

23.

Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc. 2002;50(5):799–807.CrossRefPubMed

24.

Hill S, Elhilali M, Millard R, et al. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older. Curr Med Res Opin. 2007;23(11):2697–704.CrossRefPubMed

25.

Elinoff V, Bavendam T, Glasser DB, et al. Symptom specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract. 2006;60(6):745–51.CrossRefPubMed

26.

Freeman R, Hill S, Millard R, et al. Reduced perception of urgency in treating overactive bladder with extended-release tolterodine. Obstet Gynecol. 2003;102(3):605–11.PubMed

27.

Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004;171(6 Pt 1):2311–5.CrossRefPubMed

28.

Swift S, Garely A, Dimpfl T, Payne C. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 2003;14(1):50–5.CrossRefPubMed

29.

Khullar V, Sexton CC, Thompson CL, et al. The relationship between BMI and urinary incontinence subgroups: results from EpiLUTS. Neurourol Urodyn. 2014;33(4):392–9. https://doi.org/10.1002/nau.22428.CrossRefPubMed

30.

Matsumoto S, Hashizume K, Wada N, et al. Relationship between overactive bladder and irritable bowel syndrome: a large-scale internet survey in Japan using the overactive bladder symptom score and Rome III criteria. BJU Int. 2013;111(4):647–52.CrossRefPubMed

31.

Bulchandani S, Toozs-Hobson P, Parsons M, et al. Effect of anticholinergics on the overactive bladder and bowel domain of the electronic personal assessment questionnaire (ePAQ). Int Urogynecol J. 2015;26(4):533–7.CrossRefPubMed

32.

Salvatore S, Serati M, Ghezzi F, et al. Efficacy of tolterodine in women with detrusor overactivity and anterior vaginal wall prolapse: is it the same? BJOG. 2007;114(11):1436–8.CrossRefPubMed

33.

Eckhardt MD, van Venrooij GE, Boon TA. Symptoms and quality of life versus age, prostate volume, and urodynamic parameters in 565 strictly selected men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urol. 2001;57(4):695–700.CrossRefPubMed

34.

Seki N, Yuki K, Takei M, et al. Analysis of the prognostic factors for overactive bladder symptoms following surgical treatment in patients with benign prostatic obstruction. Neurourol Urodyn. 2009;28(3):197–201.CrossRefPubMed

35.

De Boer TA, Kluivers KB, Withagen MI, et al. Predictive factors for overactive bladder symptoms after pelvic organ prolapse surgery. Int Urogynecol J. 2010;21(9):1143–9.CrossRefPubMedPubMedCentral

36.

Chui A, Huang M, Wang C, Kuo H. Higher glycosylated hemoglobin levels increase the risk of overactive bladder syndrome in patients with type 2 diabetes mellitus. Int J of Urology. 2012;19(11):995–1001.CrossRef

37.

Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64:2–6.CrossRefPubMed

38.

Bunn F, Kirby M, Pinkney E, et al. Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies. Int J Clin Pract. 2015;69(2):199–217.CrossRefPubMed

39.

Tai HC, Chung SD, Ho CH, et al. Metabolic syndrome components worsen lower urinary tract symptoms in women with type 2 diabetes. J Clin Endocrinol Metab. 2010;95(3):1143–50.CrossRefPubMed

40.

Karoli R, Bhat S, Fatima J, Priya S. A study of bladder dysfunction in women wit type 2 diabetes mellitus. Indian J Endocrinol Metab. 2014;18(4):552–7.CrossRefPubMedPubMedCentral

41.

Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101:1388–95.CrossRefPubMed

42.

Bradley CS, Kennedy CM, Nygaard IE. Pelvic floor symptoms and lifestyle factors in older women. J Women's Health. 2005;14:128–36.CrossRef

43.

Parazinni F, Chiaffarino F, Lavezzari M, et al. Risk factors for stress, urge or mixed urinary incontinence in Italy. BJOG. 2003;110:927–33.CrossRef

44.

Tikkanen KA, Auvinen A, Tiitinen A, et al. Reproductive factors associated with nocturia and urinary urgency in women: a population-based study in Finland. Am J Obstet Gynecol. 2008;199(2):153.e1–12.CrossRef

45.

Lawrence JM, Lukacz ES, Nager CW, et al. Prevalence and co-occurrence of pelvic floor disorders in community-dwelling women. Obstet Gynecol. 2008;111(3):678–85.CrossRefPubMed

46.

Chuang FC, Kuo HC. Prevalence of lower urinary tract symptoms in indigenous and non-indigenous women in eastern Taiwan. J Formos Med Assoc. 2010;109(3):228–36.CrossRefPubMed

47.

Alling Möller L, Lose G, Jørgensen T. Risk factors for lower urinary tract symptoms in women 40 to 60 years of age. Obstet Gynecol. 2000;96:446–51.CrossRefPubMed

48.

Handa VL, Harvey L, Fox HE, Kjerulff KH. Parity and route of delivery: does cesarean delivery reduce bladder symptoms later in life? Am J Obstet Gynecol. 2004;191(2):463–9.CrossRefPubMed

49.

Zhang W, Song Y, He X, et al. Prevalence and risk factors of overactive bladder syndrome in Fuzhou Chinese women. Neurourol Urodyn. 2006;25(7):717–21.CrossRefPubMed

50.

Robinson D, Cardozo L, Milsom I, et al. Oestrogens and overactive bladder. Neurourol Urodyn. 2014;33(7):1086–91.CrossRefPubMed

51.

Tseng LH, Wang AC, Chang YL, et al. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treating postmenopausal women with overactive bladder syndrome. Neurourol Urodyn. 2009;28(1):47–51.CrossRefPubMed

52.

Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. The Cochrane database of systematic reviews. 2012;10:Cd001405.

53.

Garely AD, Lucente V, Vapnek J, Smith N. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes. Ann Pharmacother. 2007;41(3):391–8.CrossRefPubMed

54.

Landis JR, Kaplan S, Swift S, Versi E. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J Urol. 2004;171(2 Pt 1):752–6.CrossRefPubMed

Title: Development of a core set of outcome measures for OAB treatment
Authors: Caroline Foust-Wright
Stephanie Wissig
Caleb Stowell
Elizabeth Olson
Anita Anderson
Jennifer Anger
Linda Cardozo
Nikki Cotterill
Elizabeth Ann Gormley
Philip Toozs-Hobson
John Heesakkers
Peter Herbison
Kate Moore
Jessica McKinney
Abraham Morse
Samantha Pulliam
George Szonyi
Adrian Wagg
Ian Milsom
Publication date: 01-12-2017
Publisher: Springer London
Published in: International Urogynecology Journal / Issue 12/2017
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-017-3481-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Development of a core set of outcome measures for OAB treatment

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2017

Validation of the Sinhala translation of the International Consultation on Incontinence Modular Questionnaire for female lower urinary tract symptoms among women in Sri Lanka

Urogynecology digest

Evidence to justify retention of transvaginal mesh: comparison between laparoscopic sacral colpopexy and transvaginal Elevate™ mesh

A case–control study of the risk factors for obstetric fistula in Tigray, Ethiopia

Demonstration of a box-stitch technique for laparoscopic uterosacral ligament suspension

Iatrogenic recto-vaginal fistula as a late consequence of failed primary repair of genital injury caused by sexual assault